Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult Subjects
NCT07791303Phase 1Completed
- Sponsor
- MIRA Pharmaceuticals, Inc.
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ketamir-2 in major depressive disorder (MDD) (7 cohorts), sponsored by MIRA Pharmaceuticals, Inc. Primary endpoints: Number of Participants with Incidence of adverse events, Number of Participants With Clinically Significant Clinical Laboratory Abnormalities and 5 more. Started Mar 2025; status: completed.
02
Drugs
Ketamir-2
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07791303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791303.